| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
InvivoChem |
| Tel: |
+1-708-310-1919 +1-13798911105 |
| Email: |
sales@invivochem.cn |
|
| | Cyclopentanepropanoic acid, α-[(forMylhydroxyaMino)Methyl]-, 2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-Methyl-4-pyriMidinyl]hydrazide, (αR)- Basic information |
| Product Name: | Cyclopentanepropanoic acid, α-[(forMylhydroxyaMino)Methyl]-, 2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-Methyl-4-pyriMidinyl]hydrazide, (αR)- | | Synonyms: | GSK132232;N-((R)-2-(Cyclopentylmethyl)-3-(2-(5-fluoro-6-((S)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-2-methylpyrimidin-4-yl)hydrazinyl)-3-oxopropyl)-N-hydroxyformamide;GSK-1322322(Lanopepden/GSK-322);LANOPEPDEN (GSK 1322322);GSK-1322322
(Lanopepden;GSK-322);GSK 1322322|||GSK-1322322B|||GSK-1322322J;Cyclopentanepropanoic acid, α-[(formylhydroxyamino)methyl]-, 2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methyl-4-pyrimidinyl]hydrazide, (αR)- | | CAS: | 1152107-25-9 | | MF: | C22H34FN7O4 | | MW: | 479.56 | | EINECS: | 629-881-5 | | Product Categories: | | | Mol File: | 1152107-25-9.mol | ![Cyclopentanepropanoic acid, α-[(forMylhydroxyaMino)Methyl]-, 2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-Methyl-4-pyriMidinyl]hydrazide, (αR)- Structure](CAS/20211123/GIF/1152107-25-9.gif) |
| | Cyclopentanepropanoic acid, α-[(forMylhydroxyaMino)Methyl]-, 2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-Methyl-4-pyriMidinyl]hydrazide, (αR)- Chemical Properties |
| density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | pka | 8.60±0.69(Predicted) | | color | Off-white to light yellow |
| | Cyclopentanepropanoic acid, α-[(forMylhydroxyaMino)Methyl]-, 2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-Methyl-4-pyriMidinyl]hydrazide, (αR)- Usage And Synthesis |
| Uses | Lanopepden (GSK 1322322) is a peptidyl peptidase (PDF) inhibitor. Lanopepden inhibits PDF activity, preventing bacterial protein synthesis, thereby exerting antibacterial activity. Lanopepden is primarily effective against Gram-positive bacteria. Lanopepden is used in the study of acute bacterial skin and skin structure infections[1]. | | References | [1] Peyrusson F, et al. Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages. Antimicrob Agents Chemother. 2015 Sep;59(9):5747-60. DOI:10.1128/AAC.00827-15 |
| | Cyclopentanepropanoic acid, α-[(forMylhydroxyaMino)Methyl]-, 2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-Methyl-4-pyriMidinyl]hydrazide, (αR)- Preparation Products And Raw materials |
|